Definitive Contract HHSN261201300070C

<p>This is a $1,499,277.00 Cost Plus Fixed Fee definitive contract awarded by the National Cancer Institute (NCI), a civilian agency, to Everyfit, Inc. (doing business as Qmedic) for research and development in the biomedical (basic research) field. The contract has a period of performance through March 14, 2018 and was awarded on September 15, 2015. This contract does not have a set-aside designation.</p>

This is a $1,698,988.00 Firm Fixed Price contract awarded by the National Cancer Institute (NCI), which is part of the U.S. Department of Health and Human Services (HHS), to Insight Genetics, Inc., a small business. The contract is for &quot;OTHER FUNCTIONS - R &amp; D BIOMEDICAL (BASIC RESEARCH)&quot; and has a total small business set-aside designation. The contract was awarded on September 20, 2012 and has an ultimate completion date of August 16, 2015. This contract award is not associated...

<p>This is a $299,999.00 Firm Fixed Price contract awarded by the National Cancer Institute, a civilian agency, to Innogenomics Technologies, L.L.C., a minority-owned small business, under the Small Business Innovation Research (SBIR) Program Phase I. The contract is for research and development in the area of biomedical (basic research). It was awarded on September 22, 2015 with a final completion date of March 21, 2017. The contract has a total small business set-aside designation.</p>

This is a federal contract awarded by the National Cancer Institute (NCI), a civilian agency, to Pointcare Genomics Corp, a small minority-owned business, for research and development in biomedical basic research. The contract is a definitive, firm-fixed price contract valued at $299,961.00 and is part of the SBIR (Small Business Innovation Research) Program Phase I. The contract has a total small business set-aside designation and was awarded on September 22, 2015, with a completion date of...

This is a $2,250,351.00 Cost Plus Fixed Fee contract awarded by the National Cancer Institute (NCI), a civilian agency, to Provid Pharmaceuticals Inc., a for-profit small business organization. The contract is for the MEDICINAL CHEMISTRY LEAD OPTIMIZATION, (PHASE II) SBIR TOPIC 198 research project under the Small Business Innovation Research (SBIR) program. The contract was awarded on August 31, 2005 and has an ultimate completion date of May 31, 2008. This contract is set aside for small...

This is a Small Business Innovation Research (SBIR) Phase I contract awarded by the National Cancer Institute (NCI), a civilian agency, to Detroit R&amp;D, Inc., a minority-owned, economically disadvantaged, woman-owned small business. The contract is for R&amp;D in biomedical basic research with a ceiling value of $299,097. The contract is a definitive, firm-fixed-price contract with a period of performance ending on September 21, 2016. This SBIR Phase I award will support the development of...

This is a $199,828 Firm Fixed Price contract awarded by the National Cancer Institute (NCI), a component of the Department of Health and Human Services, to A&amp;G Pharmaceutical, Inc. (doing business as Precision Antibody) for the development of &quot;TECHNOLOGY GENERATED ANTI-PEPTIDE CAPTURE REAGENTS FOR AFFINITY ENRICHED PROTEOMIC STUDIES.&quot; The contract has a performance period ending on July 24, 2014 and was awarded on September 25, 2013. Precision Antibody is a for-profit...

This is a $355,000.00 Firm Fixed Price definitive contract awarded by the National Cancer Institute (NCI), a civilian agency within the U.S. Department of Health and Human Services, to Immunotarget Therapeutics Inc., a woman-owned small business. The contract is for the NCI's Small Business Innovation Research (SBIR) Innovative Concept Award program, which seeks proposals for highly innovative therapies, diagnostic tools, or preventive strategies focused on pediatric and/or rare cancers. The...

<p>This is a federal contract award from the National Cancer Institute, a civilian agency within the U.S. Department of Health and Human Services, to a prime contractor. The contract has a ceiling value of $679,333.47 and was awarded on August 19, 2016 with a final completion date of September 14, 2020. The contract is a Delivery Order with a Cost Plus Fixed Fee pricing type. The place of performance is Columbia, MD. The contract does not have a set-aside designation.</p>

This is a federal contract awarded by the National Cancer Institute (NCI), a component of the U.S. Department of Health and Human Services (HHS), to A&amp;G Pharmaceutical, Inc. (doing business as Precision Antibody). The $199,380 firm-fixed-price contract is for research and development related to biomedical products and was awarded on September 14, 2012, with a completion date of September 13, 2013. The contract does not have a set-aside designation. A&amp;G Pharmaceutical, Inc. is a...